Table 2.
First-line treatment regimens, overall (2004–2018), and by first-line treatment initiation period (pre- and post-2010).
| Perioda | 2004–2018 | Pre-2010 | Post-2010 |
|---|---|---|---|
| Regimen groups, N (%)b | |||
| Patients, N | 4480 | 1415 | 3065 |
| Bor-based | 2454 (54.8) | 163 (11.5) | 2291 (74.7) |
| IMiD-based | 488 (10.9) | 429 (30.3) | 59 (1.9) |
| Chemo | 869 (19.4) | 603 (42.6) | 266 (8.7) |
| Rituximab-based | 95 (2.1) | 29 (2.0) | 66 (2.2) |
| Dara-based | 21 (0.5) | – | 21 (0.7) |
| Steroids | 49 (1.1) | 38 (2.7) | 11 (0.4) |
| ASCT | 278 (6.2) | 108 (7.6) | 170 (5.5) |
| Clinical trial | 177 (4.0) | 35 (2.5) | 142 (4.6) |
| Other regimen groups | 49 (1.1) | 10 (0.7) | 39 (1.3) |
| Individual regimens, N (%) | |||
| Patients, N | 4480 | 1415 | 3065 |
| ASCT | 278 (6.2) | 108 (7.6) | 170 (5.5) |
| VCD | 653 (14.6) | 23 (1.6) | 630 (20.6) |
| MDex | 707 (15.8) | 458 (32.4) | 249 (8.1) |
| VMD | 210 (4.7) | 44 (3.1) | 166 (5.4) |
| RD | 25 (0.6) | 8 (0.6) | 17 (0.6) |
| VD | 401 (9.0) | 79 (5.6) | 322 (10.5) |
| CTD | 357 (8.0) | 337 (23.8) | 20 (0.7) |
| Clinical trial | 177 (4.0) | 35 (2.5) | 142 (4.6) |
| Other individual regimens | 1672 (37.3) | 323 (22.8) | 1349 (44.0) |
ASCT autologous stem cell transplantation, Bor bortezomib, Chemo chemotherapy, CTD cyclophosphamide, thalidomide, and dexamethasone, Dara daratumumab, IMiD immunomodulatory drugs, MDex melphalan and dexamethasone, N number of patients, RD lenalidomide and dexamethasone, VCD bortezomib, cyclophosphamide, and dexamethasone, VD bortezomib and dexamethasone, VMD bortezomib, melphalan, and dexamethasone.
aPre- and post-2010 indicate the periods of 2004–2010 and 2011–2018, respectively.
bPercentages are calculated using the total number of patients in each column as the denominator.
Bold values indicate the number of patient subgroups pre-2010 and post-2010.